Cargando…
Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
Supercritical CO(2) loading of preformed 3D printed drug carriers with active pharmaceutical ingredients (APIs) shows great potential in the development of oral dosage forms for future personalized medicine. We designed 3D printed scaffold like drug carriers with varying pore sizes made from polylac...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069480/ https://www.ncbi.nlm.nih.gov/pubmed/33924592 http://dx.doi.org/10.3390/pharmaceutics13040543 |
_version_ | 1783683246734704640 |
---|---|
author | Schmid, Johannes Wahl, Martin A. Daniels, Rolf |
author_facet | Schmid, Johannes Wahl, Martin A. Daniels, Rolf |
author_sort | Schmid, Johannes |
collection | PubMed |
description | Supercritical CO(2) loading of preformed 3D printed drug carriers with active pharmaceutical ingredients (APIs) shows great potential in the development of oral dosage forms for future personalized medicine. We designed 3D printed scaffold like drug carriers with varying pore sizes made from polylactic acid (PLA) using a fused deposition modelling (FDM) 3D printer. The 3D printed drug carriers were then loaded with Ibuprofen as a model drug, employing the controlled particle deposition (CPD) process from supercritical CO(2). Carriers with varying pore sizes (0.027–0.125 mm) were constructed and loaded with Ibuprofen to yield drug-loaded carriers with a total amount of 0.83–2.67 mg API (0.32–1.41% w/w). Dissolution studies of the carriers show a significantly decreasing dissolution rate with decreasing pore sizes with a mean dissolution time (MDT) of 8.7 min for the largest pore size and 128.2 min for the smallest pore size. The API dissolution mechanism from the carriers was determined to be Fickian diffusion from the non-soluble, non-swelling carriers. Using 3D printing in combination with the CPD process, we were able to develop dosage forms with individually tailored controlled drug release. The dissolution rate of our dosage forms can be easily adjusted to the individual needs by modifying the pore sizes of the 3D printed carriers. |
format | Online Article Text |
id | pubmed-8069480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80694802021-04-26 Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms Schmid, Johannes Wahl, Martin A. Daniels, Rolf Pharmaceutics Article Supercritical CO(2) loading of preformed 3D printed drug carriers with active pharmaceutical ingredients (APIs) shows great potential in the development of oral dosage forms for future personalized medicine. We designed 3D printed scaffold like drug carriers with varying pore sizes made from polylactic acid (PLA) using a fused deposition modelling (FDM) 3D printer. The 3D printed drug carriers were then loaded with Ibuprofen as a model drug, employing the controlled particle deposition (CPD) process from supercritical CO(2). Carriers with varying pore sizes (0.027–0.125 mm) were constructed and loaded with Ibuprofen to yield drug-loaded carriers with a total amount of 0.83–2.67 mg API (0.32–1.41% w/w). Dissolution studies of the carriers show a significantly decreasing dissolution rate with decreasing pore sizes with a mean dissolution time (MDT) of 8.7 min for the largest pore size and 128.2 min for the smallest pore size. The API dissolution mechanism from the carriers was determined to be Fickian diffusion from the non-soluble, non-swelling carriers. Using 3D printing in combination with the CPD process, we were able to develop dosage forms with individually tailored controlled drug release. The dissolution rate of our dosage forms can be easily adjusted to the individual needs by modifying the pore sizes of the 3D printed carriers. MDPI 2021-04-13 /pmc/articles/PMC8069480/ /pubmed/33924592 http://dx.doi.org/10.3390/pharmaceutics13040543 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmid, Johannes Wahl, Martin A. Daniels, Rolf Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms |
title | Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms |
title_full | Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms |
title_fullStr | Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms |
title_full_unstemmed | Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms |
title_short | Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms |
title_sort | supercritical fluid technology for the development of 3d printed controlled drug release dosage forms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069480/ https://www.ncbi.nlm.nih.gov/pubmed/33924592 http://dx.doi.org/10.3390/pharmaceutics13040543 |
work_keys_str_mv | AT schmidjohannes supercriticalfluidtechnologyforthedevelopmentof3dprintedcontrolleddrugreleasedosageforms AT wahlmartina supercriticalfluidtechnologyforthedevelopmentof3dprintedcontrolleddrugreleasedosageforms AT danielsrolf supercriticalfluidtechnologyforthedevelopmentof3dprintedcontrolleddrugreleasedosageforms |